{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T02:36:14Z","timestamp":1769740574544,"version":"3.49.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T00:00:00Z","timestamp":1574208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Medicine and Surgery"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.amsu.2019.11.007","type":"journal-article","created":{"date-parts":[[2019,11,22]],"date-time":"2019-11-22T07:41:07Z","timestamp":1574408467000},"page":"1-4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Leukemic phase of ALK-negative anaplastic large cell lymphoma in a patient who is on androgenic steroids: A case report"],"prefix":"10.1097","volume":"49","author":[{"given":"Ganesh","family":"Kasinathan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"2","key":"10.1016\/j.amsu.2019.11.007_bib1","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.critrevonc.2012.06.004","article-title":"Anaplastic large cell lymphoma, ALK-negative","volume":"85","author":"Ferreri","year":"2013","journal-title":"Crit. Rev. Oncol.-Hematol."},{"key":"10.1016\/j.amsu.2019.11.007_bib2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2169\/internalmedicine.51.6146","article-title":"Leukemic presentation of ALK-negative anaplastic large cell lymphoma in a patient with myelodysplastic syndrome","volume":"51","author":"Tanaka","year":"2012","journal-title":"Intern. Med."},{"key":"10.1016\/j.amsu.2019.11.007_bib3","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1182\/blood-2012-11-465369","article-title":"Leukemic phase of ALK-positive anaplastic large cell lymphoma","volume":"121","author":"He","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.amsu.2019.11.007_bib4","doi-asserted-by":"crossref","first-page":"438","DOI":"10.2174\/138955711795445907","article-title":"Is there a potential immune dysfunction with anabolic androgenic steroid use? A review","volume":"11","author":"Brenu","year":"2011","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.amsu.2019.11.007_bib5","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.humpath.2003.10.013","article-title":"Absence of Epstein Barr virus in anaplastic large cell lymphoma: a study of 64 cases classified according to world health organization","volume":"35","author":"Herling","year":"2004","journal-title":"Hum. Pathol."},{"issue":"12","key":"10.1016\/j.amsu.2019.11.007_bib6","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1182\/blood.V96.12.3681","article-title":"CD30 positive anaplastic large cell lymphoma: a review of its histopathologic, genetic and clinical features","volume":"96","author":"Stein","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.amsu.2019.11.007_bib7","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1440-1827.2009.02376.x","article-title":"Anaplastic large cell lymphoma in leukemic phase: extraordinarily high white blood cell count","volume":"59","author":"Nguyen","year":"2009","journal-title":"Pathol. Int."},{"issue":"6","key":"10.1016\/j.amsu.2019.11.007_bib8","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1182\/blood-2012-01-405555","article-title":"European T-Cell Lymphoma Group. Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large cell lymphoma","volume":"120","author":"Agnelli","year":"2012","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.amsu.2019.11.007_bib9","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","article-title":"ALK-negative anaplastic large cell lymphoma is a genetically heterogenous disease with widely disparate clinical outcomes","volume":"124","author":"Castellar","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.amsu.2019.11.007_bib10","first-page":"19","article-title":"Anabolic androgenic steroids effects on the immune system: a review","volume":"4","author":"Marshal-Gradisnik","year":"2009","journal-title":"Cent. Eur. J. Biol."},{"issue":"14","key":"10.1016\/j.amsu.2019.11.007_bib11","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin Lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.amsu.2019.11.007_bib12","first-page":"2993","article-title":"Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large cell lymphoma of T\/null cell phenotype","volume":"96","author":"Suzuki","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.amsu.2019.11.007_bib13","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2007-02-074641","article-title":"Alemtuzumab and CHOP chemotherapy as first line treatment of peripheral T-cell lymphoma: result of a GITIL prospective multicentre trial","volume":"110","author":"Gallamini","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.amsu.2019.11.007_bib14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2014-10-567461","article-title":"The biology and management of systemic anaplastic large cell lymphoma","volume":"126","author":"Hapgood","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.amsu.2019.11.007_bib15","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1182\/blood-2017-10-811083","article-title":"ALCL: is it now a curable disease?","volume":"130","author":"Zinzani","year":"2017","journal-title":"Blood"}],"container-title":["Annals of Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S204908011930175X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S204908011930175X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T16:08:13Z","timestamp":1677082093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S204908011930175X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":15,"alternative-id":["S204908011930175X"],"URL":"https:\/\/doi.org\/10.1016\/j.amsu.2019.11.007","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Leukemic phase of ALK-negative anaplastic large cell lymphoma in a patient who is on androgenic steroids: A case report","name":"articletitle","label":"Article Title"},{"value":"Annals of Medicine and Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amsu.2019.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd.","name":"copyright","label":"Copyright"}]}}